Neuren completes Phelan-McDermid syndrome Phase 2 trial
Released
Released
Announcement PDF
Neuren (NEU) – ASX announcement
13 November 2023
Neuren completes Phelan-McDermid syndrome Phase 2 trial
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that all study visits are
complete in its Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome (PMS). Top-line results
from the trial are expected to be available in December 2023.
Neuren CEO Jon Pilcher commented “We are grateful to all the people at the trial sites in the United
States and in the PMS community who have enabled this groundbreaking trial to be completed as we
strive to develop a potential first therapy for PMS. We look forward to releasing next month the first
results of treatment with NNZ-2591 in children with PMS.”
Neuren is also conducting Phase 2 clinical trials of NNZ-2591 in children with three other
neurodevelopmental disorders – Pitt Hopkins syndrome, Angelman syndrome and Prader-Willi
syndrome. All four programs have been granted Orphan Drug designation by the US Food and Drug
Administration (FDA) and are being developed under Investigational New Drug (IND) applications. Each
syndrome is a seriously debilitating neurological disorder that emerges in early childhood and has no or
limited approved treatment options.
About Phelan-McDermid syndrome
Phelan-McDermid syndrome is caused by a deletion or other change in the 22q13 region of chromosome
22, which includes the SHANK3 gene, or a mutation of the gene. PMS is also known as 22q13 deletion
syndrome. The SHANK3 gene codes for the shank3 protein, which supports the structure of synapses
between nerve cells in the brain. It is estimated that between 1 in 8,000 and 1 in 15,000 people have
PMS. There are no medications, drugs, or therapies specifically for PMS, which has an overwhelming
unmet medical need.
PMS has severe quality of life impacts on those living with it, as well as on parents and siblings. The
most common characteristics are moderate to severe developmental and intellectual impairment and
developmental delay, delayed or absent speech, symptoms of autism, low muscle tone, motor delays,
mild to severe epilepsy, difficulties with toilet training and problems with eating.
Further information about PMS is available at: www.pmsf.org
1 of 2
About Neuren
Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in
early childhood and have no or limited approved treatment options.
DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of
Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an
exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation
of trofinetide.
Neuren is conducting Phase 2 trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.
Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the
United States. Orphan drug designation provides incentives to encourage development of therapies for
rare and serious diseases.
Contact:
Jon Pilcher, CEO: jpilcher@neurenpharma.com; +61 438 422 271
ASX Listing Rules information
This announcement was authorized to be given to the ASX by the board of directors of Neuren
Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124
Forward-looking Statements
This announcement contains forward-looking statements that are subject to risks and uncertainties. Such
statements involve known and unknown risks and important factors that may cause the actual results,
performance or achievements of Neuren to be materially different from the statements in this
announcement.
2 of 2
Share your feedback
Discover